|
OMEGA
Ongoing trial
 |
Author(s) |
Rauch B, Schiele R, Schneider S, Gohlke H, Diller F, Gottwik M, Steinbeck G, Heer T, Katus H, Zimmer R, Erdogan A, Pfafferott C, Senges J |
 |
Title(s) |
Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction – aims and methods of the OMEGA-study |
|
Reference(s) |
Cardiovasc Drugs Ther 2006;20:365–75 |
|
Disease |
AMI |
|
Purpose |
To evaluate the effect of highly purified omega-3 fatty acids on the rate of sudden cardiac death within 1 year of AMI |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
12 months |
|
Patients |
Aim 3800 patients (1900 omega-3 fatty acids, 1900 placebo), aged ≥ 18 years, with acute ST-elevation or non-ST-elevation MI |
|
Treatment regimen |
Omega-3-acid ethylesters 90, 1 g once daily, or placebo |
|
Results |
Not yet available |
|
|
|
